Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Andreoli

Showing results (181-190 of 221) with videos related to

Pageof 23
Sort By:
Lupus Science & Medicine|June 14, 2022
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre studyChiara Tani, Dina Zucchi, Isabell Haase, et al.
Frontiers in Immunology|November 12, 2020
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid SyndromeMaria Orietta Borghi, Asmaa Beltagy, Emirena Garrafa, et al.
Annals of the Rheumatic Diseases|August 1, 2020
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndromeMirko Scarsi, Silvia Piantoni, Enrico Colombo, et al.
Annals of the Rheumatic Diseases|May 17, 2019
EULAR recommendations for the management of antiphospholipid syndrome in adultsMaria G Tektonidou, Laura Andreoli, Marteen Limper, et al.
Medrxiv : the Preprint Server for Health Sciences|June 27, 2020
Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndromeMaria Orietta Borghi, Asmaa Beltagy, Emirena Garrafa, et al.
Journal of Autoimmunity|September 23, 2017
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide studyLuca Iaccarino, Laura Andreoli, Elena Bartoloni Bocci, et al.
Lupus|December 17, 2021
COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION)Xin Wang, Elena Gkrouzman, Danieli Castro Oliveira Andrade, et al.
RMD Open|August 8, 2022
Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task forcePavel V Ovseiko, Laure Gossec, Laura Andreoli, et al.
Annals of the Rheumatic Diseases|April 26, 2025
EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 updateLinda Rüegg, Andrea Pluma, Sabrina Hamroun, et al.
Arthritis Care & Research|September 28, 2020
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and RepositoryEcem Sevim, Diane Zisa, Danieli Andrade, et al.
Pageof 23

Showing results (181-190 of 221) with videos related to

Sort By:
Pageof 23
Lupus Science & Medicine|June 14, 2022
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre studyChiara Tani, Dina Zucchi, Isabell Haase, et al.
Frontiers in Immunology|November 12, 2020
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid SyndromeMaria Orietta Borghi, Asmaa Beltagy, Emirena Garrafa, et al.
Annals of the Rheumatic Diseases|August 1, 2020
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndromeMirko Scarsi, Silvia Piantoni, Enrico Colombo, et al.
Annals of the Rheumatic Diseases|May 17, 2019
EULAR recommendations for the management of antiphospholipid syndrome in adultsMaria G Tektonidou, Laura Andreoli, Marteen Limper, et al.
Medrxiv : the Preprint Server for Health Sciences|June 27, 2020
Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndromeMaria Orietta Borghi, Asmaa Beltagy, Emirena Garrafa, et al.
Journal of Autoimmunity|September 23, 2017
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide studyLuca Iaccarino, Laura Andreoli, Elena Bartoloni Bocci, et al.
Lupus|December 17, 2021
COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION)Xin Wang, Elena Gkrouzman, Danieli Castro Oliveira Andrade, et al.
RMD Open|August 8, 2022
Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task forcePavel V Ovseiko, Laure Gossec, Laura Andreoli, et al.
Annals of the Rheumatic Diseases|April 26, 2025
EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 updateLinda Rüegg, Andrea Pluma, Sabrina Hamroun, et al.
Arthritis Care & Research|September 28, 2020
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and RepositoryEcem Sevim, Diane Zisa, Danieli Andrade, et al.
Pageof 23